Picard Medical / SynCardia to Host Annual Business Update Featuring Key Opinion Leaders and Patient Testimonial

Core Viewpoint - Picard Medical, Inc. will host its Annual Business Update virtual call on March 25, 2026, to discuss the company's financial results and developments in its total artificial heart technology [1][2]. Group 1: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the only provider of commercially available total artificial heart technology for patients with end-stage heart failure [4]. - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada [4]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [4]. Group 2: Upcoming Event Details - The virtual call will feature business updates from management, including discussions on commercial activities and the development of the next-generation fully implantable total artificial heart platform known as Emperor [1]. - Presentations will be delivered by key executives, including the CEO, COO, and CFO, who will review the fiscal year and fourth quarter 2025 financial results [2]. - The program will include insights from leading clinicians in the cardiac surgical field and a patient testimonial regarding their experience with the SynCardia Total Artificial Heart [3].